Genfit S.A. (OTCMKTS:GNFTF) Short Interest Down 37.5% in December

Genfit S.A. (OTCMKTS:GNFTF) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 3,250 shares, a decline of 37.5% from the November 30th total of 5,200 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Genfit Stock Up 33.4%

Shares of GNFTF stock traded up $1.52 during trading hours on Monday, reaching $6.07. The stock had a trading volume of 300 shares, compared to its average volume of 200. The firm has a 50-day simple moving average of $4.07 and a 200-day simple moving average of $3.79. Genfit has a twelve month low of $4.14 and a twelve month high of $6.07.

Genfit Company Profile

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.